查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1370888

地中海型贫血诊断市场 - 2018-2028 年全球产业规模、份额、趋势、机会和预测，按类型（完整血球测试、血红蛋白测试、缺铁测试、DNA 测试等）、最终用户、按地区和竞赛

Thalassemia Diagnostic Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Type (Complete Blood Cell Test, Hemoglobin Test, Iron Deficiency Test, DNA Tests, Others), By End User, By Region, and Competition
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

由于医疗保健支出的增加、政府的支持性政策、诊断技术的进步、对地中海贫血的认识不断提高以及地中海贫血患病率的增加，预计到 2028 年，全球地中海贫血诊断市场将大幅增长。

地中海贫血是一种遗传性血液疾病，会影响血红蛋白的产生，而血红素对于体内氧气的运输至关重要。地中海贫血有两种主要类型：α地中海贫血和β地中海贫血。

全球地中海贫血诊断市场的推动因素是全球地中海贫血盛行率不断上升，以及人们对该疾病的认识不断提高。根据Cureus发表的报告，全球约1.5%的人口，约1亿人，带有B地中海贫血基因，其中东南亚、中东和地中海地区患病率最高。地中海贫血诊断市场包括地中海贫血筛检、诊断和监测的测试。这些测试包括全血球计数、血红蛋白电泳、DNA 分析等。由于越来越多地采用先进的诊断技术（例如 PCR 和基因检测），全球地中海贫血诊断市场预计将成长，这些技术在检测地中海贫血方面提供了更高的准确性和灵敏度。

市场概况
预测期 2024-2028
2022 年市场规模 52009万美元
2028 年市场规模 7.3288亿美元
2023-2028 年复合年增长率 5.86%
成长最快的细分市场 医院和诊所
最大的市场 北美洲

从地理上看，亚太地区和中东和北非地区由于地中海贫血的高盛行率而主导了地中海贫血诊断市场。然而，由于人们对地中海贫血的认识不断提高以及先进诊断技术的可用性，其他地区的市场也在成长，例如北美和欧洲，尤其是土耳其。因此，预计全球地中海贫血诊断市场的需求将在预测期内上升。

人们对地中海贫血的认识不断提高，推动了全球地中海贫血诊断市场的需求

地中海贫血是一种遗传性血液疾病，影响全世界数百万人。它是由控制血红蛋白产生的基因突变引起的，血红蛋白是一种负责在血液中携带氧气的蛋白质。地中海贫血患者产生的健康红血球较少，因此贫血、疲劳和其他併发症的风险较高。这种疾病在地中海、中东和亚洲週边国家尤其普遍，这些国家的基因突变更为常见。据估计，全球每年约有 30-40 万名儿童出生时患有遗传性 Hb 疾病，其中约 8,000 万名儿童是 B 地中海贫血的转移者。

有利的政府政策是推动地中海贫血诊断市场成长的关键驱动力

支持性政府政策一直是影响全球地中海贫血诊断市场需求的驱动力。世界各国政府已经认识到需要解决地中海贫血对其医疗保健系统日益增加的负担，并已采取措施支持地中海贫血诊断测试的开发和使用。地中海贫血患者产生的健康红血球较少，发生贫血、疲劳和其他併发症的风险较高。这种疾病在地中海、中东和亚洲週边国家尤其普遍，这些国家的基因突变更为常见。

政府支持政策影响地中海贫血诊断测试需求的主要方法是透过资金和投资。各国政府投资研发新的和改进的地中海贫血诊断测试，从而开发出更准确、更有效的测试。各国政府也提供资金以增加诊断测试的机会，特别是在地中海贫血盛行率较高的发展中国家。例如，“婚前检查”，一对即将结婚的夫妇需要接受多项检查，以检查遗传性血液疾病（例如镰状细胞性贫血和地中海贫血和镰状细胞性贫血）和传染病（例如乙型肝炎、C型肝炎、和爱滋病毒/爱滋病）在沙乌地阿拉伯。

各国政府也实施了要求对地中海贫血进行强制筛检的政策。例如，在许多国家，新生儿都会接受地中海贫血筛检，以便及早发现患有这种疾病的人并提供适当的治疗。这增加了对地中海贫血诊断测试的需求，并导致对准确和可靠的测试的更大需求。患有严重地中海贫血（如重型地中海贫血）的儿童通常会在 5 岁以下死亡，地中海贫血患者的平均寿命约为 30 岁，主要发生在资源严重受限的国家。

此外，政府的支持性政策有助于提高人们对地中海贫血以及早期诊断和治疗重要性的认识。各国政府发起了提高意识运动，教育大众了解地中海贫血及其对个人和社会的影响。这导致寻求地中海贫血诊断测试的人数增加，并有助于减少与疾病相关的耻辱感。

诊断技术的进步正在推动地中海贫血诊断市场成长的需求

诊断技术的进步在推动市场上地中海贫血诊断测试的需求方面发挥了重要作用。这些进步导致了更准确、更有效的测试的发展，从而提高了地中海贫血患者的护理品质。基因检测彻底改变了许多遗传性疾病的诊断和治疗，包括地中海贫血。它涉及分析个体的 DNA，以识别与疾病相关的特定基因突变。这种类型的测试非常准确，即使在没有表现出症状的个体中也可以检测出地中海贫血。即时检测 (POCT) 可以在床边或医生办公室快速诊断疾病。 POCT 设备是便携式的，可以在几分钟内提供结果，减少实验室检测的需要并改善患者护理。

市场区隔

全球地中海贫血诊断市场根据类型、最终用户和地区进行细分。根据类型，市场分为全血细胞 (CBC) 测试、血红蛋白测试、缺铁测试、DNA 测试等。根据最终用户，市场分为医院和诊所、诊断实验室等。依地区划分，市场分为北美、欧洲、亚太地区、南美、中东和非洲。

公司简介

Hybribio Limited、Oasis Diagnostics Corporation、ViennaLab Diagnostics GmbH、GENETEK BIOPHARMA GmbH、Devyser Diagnostics AB、亚能生物科学（深圳）有限公司、BioLab Diagnostics India Private Limited、NPT Co. Ltd 和 Bio-Rad Laboratories, Inc.是全球地中海贫血诊断市场的一些关键参与者。

报告范围：

在本报告中，除了产业趋势外，全球地中海贫血诊断市场还分为以下几类，详细资讯如下：

地中海贫血诊断市场，依类型：

  • 全血球 (CBC) 测试
  • 血红素测试
  • 缺铁测试
  • 脱氧核糖核酸测试
  • 其他的

地中海贫血诊断市场，依最终用户划分：

  • 医院和诊所
  • 诊断实验室
  • 其他的

地中海贫血诊断市场，按地区：

  • 北美洲
  • 美国
  • 加拿大
  • 墨西哥
  • 欧洲
  • 德国
  • 法国
  • 英国
  • 西班牙
  • 义大利
  • 亚太
  • 中国
  • 印度
  • 马来西亚
  • 泰国
  • 越南
  • 南美洲
  • 巴西
  • 阿根廷
  • 中东和非洲
  • 埃及
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 土耳其
  • 科威特
  • 卡达
  • 巴林

竞争格局

  • 公司简介：全球地中海贫血诊断市场主要公司的详细分析。

可用的客製化：

  • 根据给定的市场资料，TechSci Research 可根据公司的具体需求提供客製化服务。该报告可以使用以下自订选项：

公司资讯

  • 其他市场参与者（最多五个）的详细分析和概况分析。

目录

第 1 章：产品概述

  • 市场定义
  • 市场范围
    • 涵盖的市场
    • 考虑学习的年份
    • 主要市场区隔

第 2 章：研究方法

  • 研究目的
  • 基线方法
  • 主要产业伙伴
  • 主要协会和二手资料来源
  • 预测方法
  • 数据三角测量与验证
  • 假设和限制

第 3 章：执行摘要

  • 市场概况
  • 主要市场细分概述
  • 主要市场参与者概述
  • 重点地区/国家概况
  • 市场驱动因素、挑战、趋势概述

第 4 章：客户之声

第 5 章：COVID-19 对全球地中海贫血诊断市场的影响

第 6 章：临床试验分析

  • 正在进行的临床试验
  • 已完成的临床试验
  • 终止的临床试验
  • 按开发阶段分類的管道细目
  • 管道细分（按状态）
  • 按研究类型分類的管道细目
  • 按地区分類的管道明细
  • 临床试验热图

第 7 章：全球地中海贫血诊断市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型（全血细胞 (CBC) 测试、血红蛋白测试、缺铁测试、DNA 测试等）
    • 按最终使用者（医院和诊所、诊断实验室、其他）
    • 按地区
    • 按公司划分 (2022)
  • 市场地图
    • 按类型
    • 按最终用户
    • 按地区

第 8 章：北美地中海贫血诊断市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 按最终用户
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 加拿大
    • 墨西哥

第 9 章：欧洲地中海贫血诊断市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 按最终用户
    • 按国家/地区
  • 欧洲：国家分析
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利

第 10 章：亚太地区地中海贫血诊断市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 按最终用户
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 马来西亚
    • 泰国
    • 越南

第 11 章：南美洲地中海贫血诊断市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 按最终用户
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷

第 12 章：中东和非洲地中海贫血诊断市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 按最终用户
    • 按国家/地区
  • MEA：国家分析
    • 埃及地中海贫血诊断
    • 南非地中海贫血诊断
    • 沙乌地阿拉伯地中海贫血诊断
    • 阿联酋地中海贫血诊断
    • 土耳其地中海贫血诊断
    • 科威特地中海型贫血诊断
    • 卡达地中海贫血诊断
    • 巴林地中海贫血诊断

第 13 章：市场动态

  • 司机
  • 挑战

第 14 章：市场趋势与发展

  • 产品发布
  • 併购
  • 最近的发展

第 15 章：全球地中海贫血诊断市场：SWOT 分析

第16章：波特的五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 客户的力量
  • 替代产品的威胁

第17章：竞争格局

  • 商业概览
  • 公司概况
  • 产品与服务
  • 财务（上市公司）
  • 最近的发展
  • SWOT分析
    • Hybribio Limited
    • Oasis Diagnostics Corporation
    • ViennaLab Diagnostics GmbH
    • GENETEK BIOPHARMA GmbH
    • Devyser Diagnostics AB
    • Yaneng BIOscience (Shenzhen) Co., Ltd.
    • BioLab Diagnostics India Private Limited
    • NPT Co. Ltd.
    • Bio-Rad Laboratories, Inc.

第 18 章：策略建议

第 19 章：关于我们与免责声明

简介目录
Product Code: 15063

Global Thalassemia Diagnostic market is anticipated to grow considerably in the forecast period of 2028 due to rising healthcare expenditure, supportive government policy, advancements in diagnostic technologies, growing awareness about thalassemia, and increasing prevalence of thalassemia.

Thalassemia is a genetic blood disorder that affects the production of hemoglobin, which is essential for the transportation of oxygen in the body. There are two main types of thalassemia: alpha thalassemia and beta thalassemia.

The market for global thalassemia diagnostics is driven by the increasing prevalence of thalassemia worldwide, coupled with growing awareness among people about the disease. According to a published report by Cureus, around 1.5% of the world's population, or about 100 million people, carry the genes for B-thalassemia, with the highest prevalence in Southeast Asia, the Middle East, and the Mediterranean region. The market for thalassemia diagnostics includes tests for screening, diagnosis, and monitoring of thalassemia. These tests include complete blood count, hemoglobin electrophoresis, DNA analysis, and others. The global thalassemia diagnostics market is expected to grow due to the increasing adoption of advanced diagnostic technologies, such as PCR and genetic testing, which offer higher accuracy and sensitivity in detecting thalassemia.

Market Overview
Forecast Period2024-2028
Market Size 2022USD520.09 Million
Market Size 2028USD732.88 Million
CAGR 2023-20285.86%
Fastest Growing SegmentHospitals & Clinics
Largest MarketNorth America

Geographically, the Asia Pacific and MENA regions dominate the thalassemia diagnostic market, owing to the high prevalence of thalassemia in the region. However, the market is also growing in other regions, such as North America and Europe especially in Turkey, due to increasing awareness about thalassemia and the availability of advanced diagnostic technologies. Therefore, it is expected that the demand for the global thalassemia diagnostic market is going to rise in the forecast period.

Growing Awareness About Thalassemia is Propelling the Demand for the Global Thalassemia Diagnostic Market

Thalassemia is a genetic blood disorder that affects millions of people worldwide. It is caused by mutations in the genes that control the production of hemoglobin, a protein that is responsible for carrying oxygen in the blood. Individuals with thalassemia produce fewer healthy red blood cells and are therefore at a higher risk of developing anemia, fatigue, and other complications. The disorder is particularly prevalent in countries around the Mediterranean, Middle East, and Asia, where gene mutations are more usual. Globally, it is estimated that approximately 300-400 thousand children are born yearly with genetic substantial Hb diseases of which around 80 million children are transferors of B-thalassemia.

Growing awareness about thalassemia is propelling the demand for the global thalassemia diagnostic market. There is an increasing understanding of the disease among people, which has led to an increase in the number of people seeking diagnostic tests for thalassemia. The awareness has also increased the number of newborns and pregnant women being screened for thalassemia, which has further driven the demand for diagnostic tests.

The efforts of governments and healthcare organizations to educate people about the disease are one of the main drivers of the growing awareness about thalassemia. Governments around the world have launched awareness campaigns to educate people about the importance of early detection and treatment of thalassemia. These campaigns have included public service announcements, seminars, and workshops for healthcare professionals and the public. Such as Turkey Hemoglobinopathy Control Program has been initiated in 33 provinces of Turkey to screen and create awareness about B-thalassemia and its symptoms.

In addition to government initiatives, healthcare organizations, and patient advocacy groups have also played a significant role in raising awareness about thalassemia. These organizations have provided information about the disease to patients and their families, as well as to healthcare professionals. They have also offered support and resources to individuals with thalassemia and their families. The FDA or the European Medicines Agency (EMA) has granted orphan drug designation (ODD) to Beta Thalassemia drugs. Through this ODD, companies can get incentives to invest in rare disease treatments.

Another factor contributing to the growing awareness about thalassemia is the availability of information on the internet. Patients and their families can access information about the disease, including its symptoms, causes, and treatment options. The internet has also provided a platform for patient communities to connect and share their experiences, which has helped to increase awareness about the disease.

The growing awareness about thalassemia has led to an increase in the demand for thalassemia diagnostic tests. Diagnostic tests for thalassemia include blood tests, DNA analysis, and hemoglobin electrophoresis. These tests are used to screen, diagnose, and monitor the disease. With increased awareness about the disease, more people are seeking diagnostic tests, which has driven the demand for thalassemia diagnostic tests. Therefore, all these factors are expected to drive the demand for the global thalassemia diagnostic market in the forecast period.

Favorable Government Policies are Key drivers that Drive the Thalassemia Diagnostic Market Growth

Supportive government policies have been a driving force in influencing the demand for the global thalassemia diagnostic market. Governments around the world have recognized the need to address the increasing burden of thalassemia on their healthcare systems and have taken steps to support the development and use of thalassemia diagnostic tests. Individuals with thalassemia produce fewer healthy red blood cells and are at a higher risk of developing anemia, fatigue, and other complications. The disorder is particularly prevalent in countries around the Mediterranean, Middle East, and Asia, where the gene mutations are more common.

The primary method by which supportive government policies have influenced the demand for thalassemia diagnostic tests is through funding and investment. Governments have invested in research and development of new and improved diagnostic tests for thalassemia, which has led to the development of more accurate and efficient tests. Governments have also provided funding to increase access to diagnostic tests, particularly in developing countries where the prevalence of thalassemia is high. For instance, the "Premarital Screening" in which a couple planning to get married soon needs to undergo several tests to check genetic blood disorders (e.g. sickle cell anemia and thalassemia and sickle cell anemia) and infectious diseases (e.g. hepatitis B, hepatitis C, and HIV/AIDS) in Saudi Arabia.

Governments have also implemented policies that require mandatory screening for thalassemia. For example, in many countries, newborns are screened for thalassemia to identify those with the disorder early on and provide appropriate treatment. This has increased the demand for thalassemia diagnostic tests and has led to a greater need for accurate and reliable tests. Children with severe forms of thalassemia (such as thalassemia major) typically decease under 5 years of age and the average life expectancy of patients suffering from thalassemia is about 30 years, predominantly in seriously resource-constrained countries.

Furthermore, supportive government policies have helped to increase awareness about thalassemia and the importance of early diagnosis and treatment. Governments have launched awareness campaigns to educate the public about thalassemia and its impact on individuals and society. This has led to an increase in the number of people seeking diagnostic tests for thalassemia and has helped to reduce the stigma associated with the disorder.

Advancements in Diagnostic Technologies are Driving the Demand for Thalassemia Diagnostic Market Growth

Advancements in diagnostic technologies have played a significant role in driving the demand for thalassemia diagnostic tests in the market. These advancements have led to the development of more accurate and efficient tests, which have improved the quality of care for individuals with thalassemia. Genetic testing has revolutionized the diagnosis and management of many genetic disorders, including thalassemia. It involves analyzing an individual's DNA to identify specific genetic mutations associated with the disorder. This type of testing is highly accurate and can detect thalassemia even in individuals who do not exhibit symptoms. Point-of-care testing (POCT) allows for the rapid diagnosis of disease at the bedside or in the doctor's office. POCT devices are portable and can provide results in a matter of minutes, reducing the need for laboratory testing and improving patient care.

Market Segmentation

Global Thalassemia Diagnostic market is segmented based on type, end-user, and region. Based on type, the market is segmented into complete blood cell (CBC) tests, hemoglobin tests, iron deficiency tests, DNA tests, and others. Based on end-user, the market is fragmented into hospitals & clinics, diagnostic laboratories, and others. Based on region, the market is divided into North America, Europe, Asia Pacific, South America, Middle East & Africa.

Company Profiles

Hybribio Limited, Oasis Diagnostics Corporation, ViennaLab Diagnostics GmbH, GENETEK BIOPHARMA GmbH, Devyser Diagnostics AB, Yaneng BIOscience, Shenzhen) Co., Ltd., BioLab Diagnostics India Private Limited, NPT Co. Ltd., and Bio-Rad Laboratories, Inc. are some of the key players in the global thalassemia diagnostic market.

Report Scope:

In this report, global thalassemia diagnostic market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Thalassemia Diagnostic Market, By Type:

  • Complete Blood Cell (CBC) Test
  • Hemoglobin Test
  • Iron Deficiency Test
  • DNA Tests
  • Others

Thalassemia Diagnostic Market, By End User:

  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Others

Thalassemia Diagnostic Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • Asia-Pacific
  • China
  • India
  • Malaysia
  • Thailand
  • Vietnam
  • South America
  • Brazil
  • Argentina
  • Middle East & Africa
  • Egypt
  • South Africa
  • Saudi Arabia
  • UAE
  • Turkey
  • Kuwait
  • Qatar
  • Bahrain

Competitive landscape

  • Company Profiles: Detailed analysis of the major companies present in the global Thalassemia Diagnostic market.

Available Customizations:

  • With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Impact of COVID-19 on Global Thalassemia Diagnostics Market

6. Clinical Trial Analysis

  • 6.1. Ongoing Clinical Trials
  • 6.2. Completed Clinical Trials
  • 6.3. Terminated Clinical Trials
  • 6.4. Breakdown of Pipeline, By Development Phase
  • 6.5. Breakdown of Pipeline, By Status
  • 6.6. Breakdown of Pipeline, By Study Type
  • 6.7. Breakdown of Pipeline, By Region
  • 6.8. Clinical Trials Heat Map

7. Global Thalassemia Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type (Complete Blood Cell (CBC) Test, Hemoglobin Test, Iron Deficiency Test, DNA Tests, Others)
    • 7.2.2. By End User (Hospitals & Clinics, Diagnostic Laboratories, Others)
    • 7.2.3. By Region
    • 7.2.4. By Company (2022)
  • 7.3. Market Map
    • 7.3.1. By Type
    • 7.3.2. By End User
    • 7.3.3. By Region

8. North America Thalassemia Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Thalassemia Diagnostics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By End User
    • 8.3.2. Canada Thalassemia Diagnostics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By End User
    • 8.3.3. Mexico Thalassemia Diagnostics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By End User

9. Europe Thalassemia Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. Europe: Country Analysis
    • 9.3.1. Germany Thalassemia Diagnostics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By End User
    • 9.3.2. France Thalassemia Diagnostics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By End User
    • 9.3.3. United Kingdom Thalassemia Diagnostics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By End User
    • 9.3.4. Spain Thalassemia Diagnostics Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Type
        • 9.3.4.2.2. By End User
    • 9.3.5. Italy Thalassemia Diagnostics Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Type
        • 9.3.5.2.2. By End User

10. Asia-Pacific Thalassemia Diagnostics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By End User
    • 10.2.3. By Country
  • 10.3. Asia-Pacific: Country Analysis
    • 10.3.1. China Thalassemia Diagnostics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By End User
    • 10.3.2. India Thalassemia Diagnostics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By End User
    • 10.3.3. Malaysia Thalassemia Diagnostics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By End User
    • 10.3.4. Thailand Thalassemia Diagnostics Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Type
        • 10.3.4.2.2. By End User
    • 10.3.5. Vietnam Thalassemia Diagnostics Market Outlook
      • 10.3.5.1. Market Size & Forecast
        • 10.3.5.1.1. By Value
      • 10.3.5.2. Market Share & Forecast
        • 10.3.5.2.1. By Type
        • 10.3.5.2.2. By End User

11. South America Thalassemia Diagnostics Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Type
    • 11.2.2. By End User
    • 11.2.3. By Country
  • 11.3. South America: Country Analysis
    • 11.3.1. Brazil Thalassemia Diagnostics Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Type
        • 11.3.1.2.2. By End User
    • 11.3.2. Argentina Thalassemia Diagnostics Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Type
        • 11.3.2.2.2. By End User

12. Middle East and Africa Thalassemia Diagnostics Market Outlook

  • 12.1. Market Size & Forecast
    • 12.1.1. By Value
  • 12.2. Market Share & Forecast
    • 12.2.1. By Type
    • 12.2.2. By End User
    • 12.2.3. By Country
  • 12.3. MEA: Country Analysis
    • 12.3.1. Egypt Thalassemia Diagnostics Market Outlook
      • 12.3.1.1. Market Size & Forecast
        • 12.3.1.1.1. By Value
      • 12.3.1.2. Market Share & Forecast
        • 12.3.1.2.1. By Type
        • 12.3.1.2.2. By End User
    • 12.3.2. South Africa Thalassemia Diagnostics Market Outlook
      • 12.3.2.1. Market Size & Forecast
        • 12.3.2.1.1. By Value
      • 12.3.2.2. Market Share & Forecast
        • 12.3.2.2.1. By Type
        • 12.3.2.2.2. By End User
    • 12.3.3. Saudi Arabia Thalassemia Diagnostics Market Outlook
      • 12.3.3.1. Market Size & Forecast
        • 12.3.3.1.1. By Value
      • 12.3.3.2. Market Share & Forecast
        • 12.3.3.2.1. By Type
        • 12.3.3.2.2. By End User
    • 12.3.4. UAE Thalassemia Diagnostics Market Outlook
      • 12.3.4.1. Market Size & Forecast
        • 12.3.4.1.1. By Value
      • 12.3.4.2. Market Share & Forecast
        • 12.3.4.2.1. By Type
        • 12.3.4.2.2. By End User
    • 12.3.5. Turkey Thalassemia Diagnostics Market Outlook
      • 12.3.5.1. Market Size & Forecast
        • 12.3.5.1.1. By Value
      • 12.3.5.2. Market Share & Forecast
        • 12.3.5.2.1. By Type
        • 12.3.5.2.2. By End User
    • 12.3.6. Kuwait Thalassemia Diagnostics Market Outlook
      • 12.3.6.1. Market Size & Forecast
        • 12.3.6.1.1. By Value
      • 12.3.6.2. Market Share & Forecast
        • 12.3.6.2.1. By Type
        • 12.3.6.2.2. By End User
    • 12.3.7. Qatar Thalassemia Diagnostics Market Outlook
      • 12.3.7.1. Market Size & Forecast
        • 12.3.7.1.1. By Value
      • 12.3.7.2. Market Share & Forecast
        • 12.3.7.2.1. By Type
        • 12.3.7.2.2. By End User
    • 12.3.8. Bahrain Thalassemia Diagnostics Market Outlook
      • 12.3.8.1. Market Size & Forecast
        • 12.3.8.1.1. By Value
      • 12.3.8.2. Market Share & Forecast
        • 12.3.8.2.1. By Type
        • 12.3.8.2.2. By End User

13. Market Dynamics

  • 13.1. Drivers
  • 13.2. Challenges

14. Market Trends & Developments

  • 14.1. Product Launches
  • 14.2. Mergers & Acquisitions
  • 14.3. Recent Developments

15. Global Thalassemia Diagnostics Market: SWOT Analysis

16. Porter's Five Forces Analysis

  • 16.1. Competition in the Industry
  • 16.2. Potential of New Entrants
  • 16.3. Power of Suppliers
  • 16.4. Power of Customers
  • 16.5. Threat of Substitute Products

17. Competitive Landscape

  • 17.1. Business Overview
  • 17.2. Company Snapshot
  • 17.3. Products & Services
  • 17.4. Financials (In case of listed companies)
  • 17.5. Recent Developments
  • 17.6. SWOT Analysis
    • 17.6.1. Hybribio Limited
    • 17.6.2. Oasis Diagnostics Corporation
    • 17.6.3. ViennaLab Diagnostics GmbH
    • 17.6.4. GENETEK BIOPHARMA GmbH
    • 17.6.5. Devyser Diagnostics AB
    • 17.6.6. Yaneng BIOscience (Shenzhen) Co., Ltd.
    • 17.6.7. BioLab Diagnostics India Private Limited
    • 17.6.8. NPT Co. Ltd.
    • 17.6.9. Bio-Rad Laboratories, Inc.

18. Strategic Recommendations

19. About Us & Disclaimer